$0.00
AroCell TK210 ELISA is intended for the measurement of Thymidine Kinase 1 (TK1) total protein in human serum. This is an alternative methodology to measuring TK1 activity for use as an oncology biomarker.
Thymidine Kinase 1
Thymidine Kinase 1 (TK1) is a key serum protein to investigate as an oncology biomarker. Ongoing research is being done to uncover its potential for analytical/screening research, early efficacy research of new therapeutics and recurrence research. Clinical research studies related to breast, prostate, lung and bladder cancers are underway, but many questions remain to be answered about how to use TK1 as a reliable serum biomarker and offer more biomarker options to cancer researchers across tumor types.
Thymidine Kinase 1 (TK1) has been long known as a valuable biomarker of cellular proliferation. Elevated levels of serum TK1 enzyme activity is found in subjects with many forms of cancer including leukemia, lymphoma, prostate, breast, lung, sarcoma, and colon. However, previous methods have been based on enzyme activity measurements that are complex, subject to interferences, and underestimate the serum TK1 found in subjects with solid tumors. A sensitive and specific TK1 immunoassay can meet these challenges.
The Benefits of the AroCell TK210 ELISA kit:
Serum TK1 exists as many forms with differing molecular weights and enzyme activities, leading to potential underestimation using enzyme activity methods. Also, much of the serum TK1 in subjects with solid tumors has been enzymatically deactivated and found as multimeric aggregates. However, all TK1 express the TK 210 epitope. The AroCell TK 210 ELISA kit, based on monoclonal antibodies specific to TK 210, enables their detection. Furthermore, the unique sample dilution buffer breaks up the high molecular weight TK1 complexes, allowing complete TK 210 detection, leading to greater consistency between samples. The AroCell TK 210 ELISA kit is a standard microtiter ELISA providing same-day results. Each kit is sufficient for a standard curve, control, and 40 samples in duplicate. All necessary components are provided.
The AroCell TK 210 ELISA Kit in Studying Drug Effects:
Much of the serum TK1 found in subjects with solid tumors is enzymatically inactive and found in aggregates leading to underestimation of TK1 and lower sensitivity. Because of this, TK1 has not been widely used to study solid tumors. However, all TK1 express the TK 210 epitope. The AroCell TK 210 ELISA kit detects all the TK1 complexes, leading to greater sensitivity and potential clinical value.
General Benefits of the TK 210 ELISA:
Benefits of TK 210 ELISA for Clinical Research Studies:
Benefits of TK 210 ELISA for Xenograft Studies:
Benefits to Cell Culture:
TK1 is a useful biomarker for analyzing efficacy, tolerance, and dose response
The Arocell TK210 is a complementary product to the VLV product line that detects total CK18 and caspase cleavage CK18. Total CK18 is detected with M65 ELISA and indicates total cell death; while the M30 Apoptosense® specifically detects caspase cleaved CK18 (ccCK18) and indicates apoptotic cell death. Used together, these products can paint a complete picture of cell proliferation and cell death for clinical research studies in oncology.
AroCell TK210 ELISA is labeled For Research Use Only in the USA and Canada.
Each kit is sufficient for a standard curve, control, and 40 samples in duplicate. All necessary components are provided.
The kit can be used on three separate occasions.
Assay format: | Microplate sandwich ELISA |
Size: | 1 × 96 wells |
Dynamic Range: | 0–17 µg/L |
Precision: | 1.85 µg/L (5.1%) 11.53 µg/L (3%) |
Incubation Time: | 4.75 h |
Sample Type: | Serum |
Sample Size: | 180 µL |
Species: | Human |
Controls are included